Mark Straley, Jan Egberts
Agendia has appointed Mark Straley its CEO, succeeding Jan Egberts, who has served as the interim CEO since October 2014.
Straley has more than 25 years of experience in developing and commercializing clinical diagnostics and laboratory services and most recently was president, anatomical pathology at Thermo Fisher Scientific. Prior to that, he was president and CEO of Metamark Genetics. Between 2005 and 2010, Straley was worldwide vice president of marketing, and then the worldwide president of Johnson & Johnson's Ortho Clinical Diagnostics.